EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway

Xiaoying Zhang, Yu Mao, Jiaxing Wu, Xinyu Deng, Huanhuan Wang, Zhiqiang Kang

Frontiers in Endocrinology · 18.08.2026 · 17

DOI: 10.3389/fendo.2026.1903580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 18.08.2026. Verfasst von Xiaoying Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Glucosides, NF-kappa B, Muscle Fibers, Skeletal, Glycation End Products, Advanced. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Empagliflozin is an established sodium-glucose cotransporter 2 inhibitor with reported anti-inflammatory activity, but its effects on advanced glycation end product/high-glucose-induced inflammatory injury in skeletal muscle cells remain unclear.

Methods

A GEO-derived transcriptomic dataset from gastrocnemius muscle of type 2 diabetes mellitus rats was analyzed to screen pathways associated with diabetes-related skeletal muscle injury, and molecular docking was performed to explore the possible structural compatibility between empagliflozin and RAGE. Differentiated C2C12 myotubes were exposed to AGE-BSA under high-glucose conditions and treated with empagliflozin. Cell viability was assessed using CCK-8, and RAGE, NF-κB, IL-6, and TNF-α were evaluated by qRT-PCR, Western blotting, immunofluorescence, and ELISA.

Results

Bioinformatic enrichment highlighted AGE-RAGE signaling and inflammation-related NF-κB pathways in diabetic skeletal muscle. Molecular docking provided a computational structural hypothesis suggesting possible compatibility between empagliflozin and human RAGE involving Asp160. In AGE-BSA/high-glucose-stimulated C2C12 myotubes, empagliflozin improved cell viability and was accompanied by reduced RAGE expression, lower NF-κB phosphorylation and immunofluorescence-based nuclear accumulation, and lower IL-6 and TNF-α expression and secretion.

Discussion

Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammatory injury in C2C12 myotubes, and this effect is associated with reduced activation of RAGE/NF-κB-related inflammatory signaling. Further gain- or loss-of-function experiments and validation in diabetic animal models are required to determine whether this pathway is causally involved and whether the observed cell-based effect can be translated into an in vivo setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesNF-kappa BMuscle Fibers, SkeletalGlycation End Products, AdvancedGlucoseReceptor for Advanced Glycation End ProductsInflammationBenzhydryl CompoundsSerum Albumin, BovineAnimalsSignal TransductionMiceRatsCell LineMolecular Docking SimulationCell SurvivalDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

AGE-RAGE signalingC2C12 myotubesNF-κBdiabetes-related skeletal muscle injuryempagliflozininflammation

Substanzen

GlucosidesNF-kappa BGlycation End Products, AdvancedempagliflozinGlucoseReceptor for Advanced Glycation End ProductsBenzhydryl CompoundsSerum Albumin, Bovineadvanced glycation end products-bovine serum albumin

Autor:innen und Institutionen

  • Department of Endocrinology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China.

Zitieren

APA

Zhang, X., Mao, Y., Wu, J., Deng, X., Wang, H., & Kang, Z. (2026). Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1903580

Vancouver

Zhang X, Mao Y, Wu J, Deng X, Wang H, Kang Z. Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1903580

BibTeX
@article{Zhang2026,
  author = {Zhang, Xiaoying and Mao, Yu and Wu, Jiaxing and Deng, Xinyu and Wang, Huanhuan and Kang, Zhiqiang},
  title = {Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1903580}
}
Kostenlos starten →